Halothane reduces release of adenosine, inosine, and lactate with ischemia and reperfusion in isolated hearts.
We investigated the protective effects of halothane on cardiac function of isolated hearts during global hypoperfusion and reperfusion by examining halothane's effects on altering coronary flow, myocardial oxygen utilization (MVO2), and release of adenosine (ADE), inosine (INO), and lactate (LAC). Isolated perfused guinea pig hearts were divided into three groups of perfusion at 25% (14 mm Hg), 10% (5.5 mm Hg), and 0% (no perfusion) from control perfusion pressure (PP, 55 mm Hg). Each of these PP groups was subdivided into three subgroups and perfused without halothane (control), with 0.23 +/- 0.01 mM (0.74%) halothane, or with 0.51 +/- 0.01 mM (1.65%) halothane. Halothane was present 10 min before reducing PP, during reduced PP (30 min), and for 10 min after reducing PP. Hypoperfusion was followed by 40 min of reperfusion at the control (100%, 55 mm Hg) PP. An additional group of control hearts was followed for the same period without reducing PP or perfusing with halothane. Exposure to 0.74% and 1.65% halothane, before reducing PP, decreased MVO2 and percent oxygen extraction (% O2E), but produced no significant change in coronary flow or release of ADE, ISO, or LAC. During early hypoperfusion (10 min) at 25% PP, 1.65% halothane significantly reduced release of ADE, INO, and LAC. During late hypoperfusion (40 min) the differences in LAC release diminished, but release of ADE and INO remained lower in the 1.65% halothane group. With early reperfusion there was a large increase in release of these metabolites, that was dependent on the decrease in perfusion pressure.(ABSTRACT TRUNCATED AT 250 WORDS)
Buljubasic
N
N
Department of Anesthesiology, Medical College of Wisconsin, Milwaukee 53226.
Stowe
D F
DF
Marijic
J
J
Roerig
D L
DL
Kampine
J P
JP
Bosnjak
Z J
ZJ
D000241:Adenosine / Q000378:metabolism*; D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects; D006168:Guinea Pigs; D006221:Halothane / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects; D007288:Inosine / Q000378:metabolism*; D007773:Lactates / Q000378:metabolism*; D015425:Myocardial Reperfusion; D009206:Myocardium / Q000378:metabolism*; D010101:Oxygen Consumption
D007773:Lactates; D007288:Inosine; D000241:Adenosine; D006221:Halothane